Trials / Not Yet Recruiting
Not Yet RecruitingNCT07389590
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ublituximab | Ublituzimab will be administered via IV infusion as specified throughout the study period. |
| DRUG | Ocrelizumab | Ocrelizumab will be administered via IV infusion as specified throughout the treatment period. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2028-10-01
- Completion
- 2029-03-01
- First posted
- 2026-02-05
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07389590. Inclusion in this directory is not an endorsement.